全文获取类型
收费全文 | 10896篇 |
免费 | 564篇 |
国内免费 | 56篇 |
专业分类
耳鼻咽喉 | 99篇 |
儿科学 | 731篇 |
妇产科学 | 283篇 |
基础医学 | 1169篇 |
口腔科学 | 228篇 |
临床医学 | 735篇 |
内科学 | 2176篇 |
皮肤病学 | 316篇 |
神经病学 | 538篇 |
特种医学 | 434篇 |
外国民族医学 | 1篇 |
外科学 | 1541篇 |
综合类 | 295篇 |
一般理论 | 11篇 |
预防医学 | 444篇 |
眼科学 | 499篇 |
药学 | 1125篇 |
中国医学 | 52篇 |
肿瘤学 | 839篇 |
出版年
2023年 | 69篇 |
2022年 | 146篇 |
2021年 | 323篇 |
2020年 | 169篇 |
2019年 | 236篇 |
2018年 | 272篇 |
2017年 | 221篇 |
2016年 | 277篇 |
2015年 | 271篇 |
2014年 | 375篇 |
2013年 | 532篇 |
2012年 | 725篇 |
2011年 | 783篇 |
2010年 | 438篇 |
2009年 | 349篇 |
2008年 | 566篇 |
2007年 | 536篇 |
2006年 | 456篇 |
2005年 | 436篇 |
2004年 | 405篇 |
2003年 | 343篇 |
2002年 | 331篇 |
2001年 | 301篇 |
2000年 | 305篇 |
1999年 | 253篇 |
1998年 | 132篇 |
1997年 | 103篇 |
1996年 | 117篇 |
1995年 | 98篇 |
1994年 | 68篇 |
1993年 | 68篇 |
1992年 | 124篇 |
1991年 | 164篇 |
1990年 | 134篇 |
1989年 | 131篇 |
1988年 | 131篇 |
1987年 | 90篇 |
1986年 | 94篇 |
1985年 | 105篇 |
1984年 | 75篇 |
1983年 | 76篇 |
1982年 | 37篇 |
1980年 | 41篇 |
1979年 | 67篇 |
1978年 | 52篇 |
1977年 | 46篇 |
1973年 | 38篇 |
1972年 | 41篇 |
1971年 | 44篇 |
1968年 | 44篇 |
排序方式: 共有10000条查询结果,搜索用时 312 毫秒
41.
N. Jain N. Kemp O. Adeyemo P. Buchanan T. W. Stone 《British journal of pharmacology》1995,116(3):2127-2133
1. Purine analogues have been examined for anxiolytic- and anxiogenic-like activity in mice, by use of the elevated plus-maze. 2. The selective A1 receptor agonist, N6-cyclopentyladenosine (CPA) had marked anxiolytic-like activity at 10 and 50 microg kg(-1), with no effect on locomotor performance at these doses. 3. The A1 selective adenosine receptor antagonist, 1,3-dipropyl-8-cyclopentylxanthine (CPX) had no significant effect on anxiety-related measures or locomotor behaviour, but blocked the anxiolytic-like activity of CPA. The hydrophilic xanthine, 8-(p-sulphophenyl) theophylline did not prevent anxiolysis by CPA. 4. Caffeine had anxiogenic-like activity at 30 mg kg(-1) which was prevented by CPA at 50 micro kg(-1). 5. The A2 receptor agonist, N6-[2-(3,5-dimethoxyphenyl)-2(2-methylphenyl)-ethyl]adenosine (DPMA) had no effect on anxiety behaviour but depressed locomotor activity at the highest dose tested of 1 mg kg(-1). The A2 receptor antagonist, 1,3-dimethyl-l-propargylxanthine (DMPX) had no effect on anxiety-related measures or locomotion and did not modify the anxiolytic-like activity of CPA. 6. Administration of DPMA in combination with anxiolytic doses of CPA prevented the anxiolytic-like activity of the latter. 7. The results suggest that the selective activation of central A1 adenosine receptors induces anxiolytic-like behaviour, while the activation of A2 sites causes locomotor depression and reduces the effects of A1 receptor activation. The absence of any effect of CPX alone suggests that the receptors involved in modulating behaviour in the elevated plus-maze in mice are not activated tonically by endogenous adenosine. 相似文献
42.
43.
44.
Tetrabenazine (TBZ), a presynaptic dopamine depletor and postsynaptic dopamine receptor blocker, is widely used for the treatment of hyperkinetic movement disorders in adults. However, reports of its use in children are limited. We review the efficacy and tolerability of TBZ therapy in 31 children with hyperkinetic movement disorders refractory to other medications. TBZ was effective in reducing the severity of movement disorders resistant to treatment with other medicines. When compared to adult patients, pediatric patients required higher doses. Side effects were similar to the adult population; however, children had a lower incidence of drug-induced Parkinsonism. 相似文献
45.
46.
47.
48.
Dinesh Singh Ajit K. Banerji Bilikere S. Dwarakanath Rajendra P. Tripathi Jaganath P. Gupta T. Lazar Mathew Turuga Ravindranath Viney Jain 《Strahlentherapie und Onkologie》2005,355(1):507-514
Background and Purpose:
Higher rates of glucose utilization and glycolysis generally correlate with poor prognosis in several types of malignant tumors. Own earlier studies on model systems demonstrated that the nonmetabolizable glucose analog 2-deoxy-D-glucose (2-DG) could enhance the efficacy of radiotherapy in a dose-dependent manner by selectively sensitizing cancer cells while protecting normal cells. Phase I/II clinical trials indicated that the combination of 2-DG, at an oral dose of 200 mg/kg body weight (BW), with large fractions of γ-radiation was well tolerated in cerebral glioma patients. Since higher 2-DG doses are expected to improve the therapeutic gain, present studies were undertaken to examine the tolerance and safety of escalating 2-DG dose during combined treatment (2-DG + radiotherapy) in glioblastoma multiforme patients. 相似文献49.
50.